Biogen
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
225 Binney St, Cambridge, Massachusetts,...Phone Number
(781) 464-2000Website
www.biogen.comRevenue
$9.9 BillionStock Symbol
BIIBIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
23
22
1
3
3
2
About Biogen
Biogen is a U.S.-based biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological and neurodegenerative diseases. Its core portfolio includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and other rare neurological disorders, supported by advanced research in neuroscience, biologics, and gene-based therapies.Explore more
Biogen Org Chart
AE
Reporting Analyst
TC
Controller
VC
Controller
AL
Controller
KP
Financial Controller
SC
Internal Greater Controller (China)
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biogen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Biogen has new funding data
Biogen, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Biogen recently announced quarterly report
Check out if Biogen is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Biogen
Check if Biogen has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Biogen launches new products
Click to see if Biogen had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Biogen as Masked Content
Find 2 more new buyers
Compare Similar Companies to Biogen
Compare insights from companies similar to Biogen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Biogen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Biogen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Biogen.
Biogen Tech Stack
A closer look at the technologies used by Biogen
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Open Position
Open Position
Open Position
Biogen News & Media
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular atrophy (SMA). Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvementEULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that fourteen abstracts highlighting data from its nephrology portfolio, including EMPAVELI® (pegcetacoplan) and investigational felzartamab, have been accepted for presentation at the 63rd European Renal Association Congress (ERA) and the 2026 American Transplant Congress (ATC).INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biogen
Sign Up For FreeTo access detailed company insights
Biogen is a U.S.-based biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological and neurodegenerative diseases. Its core portfolio includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and other rare neurological disorders, supported by advanced research in ne... Read More
